Compare Ascendis Pharma A/S (ASND) vs Fubotv Inc (FUBO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Fubotv Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Fubotv Inc trades at $9.23 (market cap $270.29M). The key difference: Ascendis Pharma A/S is far larger — about 65.6× Fubotv Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals.
| ASND | FUBO | |
|---|---|---|
Market Cap | $17.74B | $270.29M |
Sector | Health | Technology |
52-Week High | $277.18 | $54.72 |
52-Week Low | $163.32 | $8.09 |
Enterprise Value | $18.11B | $440.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
FUBO stock trades at $9.18, down 3.57% on the day, amid a bearish technical signal. The company shows improving fundamentals with revenue reaching $1.62B in 2024 and a projected net income margin of 7.61% for 2025, while valuation ratios like P/E of 2.39 and P/S of 0.18 appear attractive. Recent news highlights the appointment of Alisa Bowen as CEO, bringing media industry experience.
The outlook is mixed; analyst consensus is a Buy with a $16.25 price target, but risks include persistent negative cash flows, high debt levels, and competitive pressures in streaming. Investor sentiment is cautious pending execution of the new leadership's strategy and path to sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →
